The concept of myeloid protection through CDK4/6 inhibition holds significant importance in cancer therapy, as chemotherapy remains a cornerstone in the treatment of many cancers, and its myelosuppressive effects often compromise therapeutic outcomes [8]. This evidence concerns the gene CDK4 and cancer.